Rescuing larvae from missile-damaged lab, Weizmann team finds cells that not only beat back death, but also multiply and spur ...

After J.P. Morgan, biotech’s bold promises meet real-world challenges. In 2026, success starts with a CDMO partner who ...

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...

In the race to bring new biologics to market, development teams are constantly balancing speed, quality, and regulatory ...

For the last two years, the cultivated meat industry has been experiencing growing pains. Many startups have shrunk, shut ...

The discovery that tissues use electricity to expel unhealthy cells is part of a surge of renewed interest in the currents ...

Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.

Aragen Biologics launched CHOMax™, a new cell line development and early manufacturing platform that the company says supports an integrated path from DNA to IND-enabling clinical supply for suitable ...

Validated next-generation sequencing soon will become necessary in ensuring the safety and efficacy of cell and gene ...

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing ...

Cell line creation is a major success factor in biologics manufacturing. It establishes the basis for product yield, quality, and long-term process stability. However, despite significant ...

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex molecules SEATTLE--(BUSINESS WIRE)-- As drug ...